H股发行上市
Search documents
上市进程稳步推进,豪威集团刊发H股发行聆讯后资料集
Ju Chao Zi Xun· 2025-12-17 13:53
Core Viewpoint - The announcement by the company indicates significant progress in the H-share issuance and listing process on the Hong Kong Stock Exchange, with key milestones achieved in the application and approval stages [2] Group 1: H-Share Issuance Progress - On June 27, 2025, the company submitted its application for H-share issuance and published the relevant application materials to the Hong Kong Stock Exchange [2] - On December 9, 2025, the company received a notification from the China Securities Regulatory Commission confirming the registration of the overseas issuance and listing [2] - A listing hearing was held by the Hong Kong Stock Exchange Listing Committee on December 11, 2025, to review the company's application for H-share issuance [2] Group 2: Compliance and Information Disclosure - The published post-hearing information set is prepared in accordance with the requirements of the Hong Kong Stock Exchange and the Securities and Futures Commission of Hong Kong [2] - The purpose of the publication is to provide relevant information to the public and qualified investors in Hong Kong [2]
新国都向香港联交所递交H股发行上市申请并刊发申请资料
Zhi Tong Cai Jing· 2025-11-26 00:33
Core Viewpoint - The company, New Guodu (300130), has submitted an application for issuing overseas listed shares (H shares) and listing on the main board of the Hong Kong Stock Exchange on November 25, 2025 [1] Group 1 - The application for H shares listing has been officially filed with the Hong Kong Stock Exchange [1] - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange's website on the same day [1]
沃尔核材:H股发行上市有益于公司的长远发展
Zheng Quan Ri Bao· 2025-11-24 09:07
Core Viewpoint - The company believes that the issuance and listing of H-shares will benefit its long-term development by enhancing financing channels and supporting ongoing investments in technology research, capacity construction, and overseas market expansion [2]. Group 1 - The H-share issuance will help the company broaden its financing channels [2]. - It will provide strong support for continuous investment in technology research, capacity construction, and overseas market layout [2]. - The move is expected to enhance the company's core competitiveness [2]. Group 2 - The H-share issuance will facilitate the company's internationalization strategy [2]. - It aims to improve the company's international brand image [2]. - The company will consider various factors to reasonably arrange related work [2].
广东领益智造股份有限公司 关于向香港联交所递交H股发行上市申请并刊发申请资料的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-11-21 00:35
Core Viewpoint - Guangdong Lingyi Intelligent Manufacturing Co., Ltd. has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange, indicating a strategic move to access international capital markets [1][2]. Group 1: Application Details - The application for the H-share issuance was submitted on November 20, 2025, and the related materials were published on the Hong Kong Stock Exchange website on the same day [1]. - The issuance will be limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments under Chinese laws [1][2]. Group 2: Regulatory Considerations - The issuance and listing are subject to approvals from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating that the process involves multiple regulatory layers [2]. - The company will not publish the application materials on domestic stock exchange websites or media, but will provide links for domestic investors to access the information on the Hong Kong Stock Exchange website [1][2].
苏州纳芯微电子股份有限公司关于刊发H股发行聆讯后资料集的公告
Shang Hai Zheng Quan Bao· 2025-11-19 18:42
Core Viewpoint - Suzhou Naxin Microelectronics Co., Ltd. is in the process of applying for the issuance of H-shares and listing on the Hong Kong Stock Exchange, with the necessary documentation submitted and regulatory approvals pending [1][5]. Group 1: Application Process - The company submitted its application for H-share issuance and listing to the Hong Kong Stock Exchange on April 25, 2025, and published the application materials on the same day [2]. - On October 27, 2025, the company resubmitted its application to the Hong Kong Stock Exchange and published the updated application materials [2]. - The company received a confirmation from the China Securities Regulatory Commission regarding the filing for overseas issuance and listing on October 21, 2025 [3]. Group 2: Listing Hearing and Information Disclosure - A listing hearing was held by the Hong Kong Stock Exchange Listing Committee on October 30, 2025, to review the company's application for issuance and listing [4]. - The company published a post-hearing information package on the Hong Kong Stock Exchange website, which is intended to provide information to the public and qualified investors [4]. - The company will not publish the post-hearing information package on domestic stock exchange websites but will provide links for A-share investors to access the information [4]. Group 3: Regulatory Approvals - The issuance and listing are subject to final approvals from the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, indicating that there are uncertainties regarding the process [5].
苏州纳芯微电子股份有限公司第三届董事会第二十一次会议决议公告
Shang Hai Zheng Quan Bao· 2025-11-18 18:54
Group 1 - The board of directors of Suzhou Naxin Microelectronics Co., Ltd. held its 21st meeting of the third session on November 18, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the proposal regarding the global offering of H shares and related arrangements for listing on the Hong Kong Stock Exchange, authorizing relevant personnel to handle specific matters related to the issuance and listing [2][5] - The board also approved the confirmation and commitment related to the H share issuance, ensuring compliance with relevant legal requirements for the prospectus [5][6] Group 2 - The board approved amendments to the internal governance system applicable after the H share issuance, allowing the chairman and authorized personnel to make necessary adjustments to the governance documents based on legal and regulatory requirements [7][8] - The revised internal governance system will take effect upon the listing of the H shares on the main board of the Hong Kong Stock Exchange, automatically invalidating the current governance system [7][8]
四川百利天恒药业股份有限公司 关于发行H股并上市的进展公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-11-13 05:10
Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is progressing with its plan to issue H-shares and list on the Hong Kong Stock Exchange, but has decided to delay the global offering and listing due to current market conditions [1][2]. Group 1 - The company has published its H-share prospectus and details regarding the public offering on November 7, 2025 [1]. - The subscription for the H-shares is limited to qualified overseas investors and certain domestic institutional investors as per relevant regulations [2]. - The company will not publish the announcement on domestic stock exchanges or media, and relevant information can be accessed on the Hong Kong Stock Exchange website [2].
传音控股(688036)披露拟发行H股并在港交所上市,11月12日股价下跌2.29%
Sou Hu Cai Jing· 2025-11-12 14:16
Core Points - Transsion Holdings (688036) closed at 65.85 yuan on November 12, 2025, down 2.29% from the previous trading day, with a total market capitalization of 75.806 billion yuan [1] - The company announced its first extraordinary general meeting of 2025, scheduled for November 28, 2025, to discuss several key proposals, including the issuance of H-shares and listing on the Hong Kong Stock Exchange [1] Group 1: Stock Performance - The stock opened at 67.28 yuan, reached a high of 67.29 yuan, and a low of 65.77 yuan, with a trading volume of 6.58 billion yuan and a turnover rate of 0.86% [1] Group 2: Upcoming Shareholder Meeting - The extraordinary general meeting will combine on-site and online voting, addressing proposals such as issuing H-shares, amending the company’s articles of association, electing independent directors, and appointing an auditing firm for the H-share issuance [1] - The record date for shareholders to participate in the meeting is November 24, 2025 [1]
四川百利天恒药业股份有限公司 关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-11-08 00:19
Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with various steps completed in the application and approval process [1][2][3][4]. Group 1: Application and Approval Process - The company submitted its application for H-share issuance to the Hong Kong Stock Exchange on July 10, 2024, and published the application materials on the same day [2]. - The company resubmitted its application on January 21, 2025, and September 29, 2025, in accordance with the Hong Kong Stock Exchange's regulations [2]. - On December 11, 2024, the China Securities Regulatory Commission confirmed the company's application for overseas issuance and listing [3]. - The Hong Kong Stock Exchange's listing committee held a hearing on December 19, 2024, to review the company's application [3]. Group 2: H-share Offering Details - The total number of H-shares to be issued is 8,634,300, with 863,500 shares allocated for public offering in Hong Kong, representing approximately 10% of the total, and 7,770,800 shares for international offering, representing approximately 90% [6]. - The price range for the H-share issuance is preliminarily set between HKD 347.50 and HKD 389.00 [6]. - The public offering in Hong Kong commenced on November 7, 2025, and is expected to conclude on November 12, 2025, with the issuance price to be announced by November 14, 2025 [6]. - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on November 17, 2025 [6].
调研速递|山推股份接待华源证券调研 三季度净利润同比增长15.67%
Xin Lang Cai Jing· 2025-11-04 11:39
Core Viewpoint - Shantui Construction Machinery Co., Ltd. has shown stable revenue growth and significant profit increase in Q3 2025, alongside ongoing stock buyback and H-share issuance preparations [3][4][5]. Group 1: Q3 Performance - In Q3 2025, the company achieved a revenue of 10.488 billion yuan, a year-on-year increase of 2.36% [3] - The net profit attributable to shareholders was 838 million yuan, reflecting a year-on-year growth of 15.67% [3] - The net profit after deducting non-recurring gains and losses was 823 million yuan, with a year-on-year increase of 24.40% [3] - Basic earnings per share were 0.5595 yuan, up 15.84% year-on-year [3] Group 2: Stock Buyback Progress - As of October 31, 2025, the company has repurchased 10,762,650 shares, accounting for 0.72% of the total share capital [4] - The repurchase price ranged from 8.64 yuan to 9.74 yuan per share [4] - The company plans to continue the buyback based on market conditions and will fulfill information disclosure obligations [4] Group 3: H-Share Issuance Project - The company is progressing with its H-share issuance and listing on the Hong Kong Stock Exchange [5] - Key milestones include receiving approval from the controlling shareholder on August 14, 2025, and submitting the IPO application to the Hong Kong Stock Exchange on August 28, 2025 [5] - The company has responded to supplementary material requests from the China Securities Regulatory Commission and is preparing responses to inquiries from the Hong Kong Stock Exchange [5] Group 4: On-Site Visit - The research team conducted an on-site visit to the company's exhibition hall and main engine factory, gaining insights into the product matrix and application scenarios [6] - The visit provided a comprehensive understanding of the company's operational performance, capital operations, and strategic planning [6]